Violation Tracker Global

Basic Search | Summaries | Advanced Search

One Time Payment

US$5 fixed price

Download up to 50 records using a credit card to purchase your current search results.

If your search contains more than 50 records, you will receive only the first 50 based on the sorting chosen at the time of purchase. Downloads will contain all fields shown in the individual records, not only those visible on the search results page. If your search is 50 records or higher, a subscription might be a better option.

If your search contains fewer than 50 records, the balance cannot be used for a separate search.

Existing subscribers

Please log in if you already subscribed

Ongoing Subscriptions

Tier 1 US$25 Monthly or US$250 Yearly
Up to 100 downloaded records per search.

Tier 2 US$45 Monthly or US$450 Yearly
Up to 500 downloaded records per search.

Tier 3 US$150 Monthly or US$1500 Yearly
Up to 1000 downloaded records per search.

Go to the subscription purchase page

Once you subscribe, you will be able to download your current search results. Downloads will contain all fields shown in the individual records, not only those visible on the search results page.

If the number of records in your search results exceeds the limit of your subscription tier, your download will include the maximum number based on the sorting chosen at the time of the download.

Violation Tracker Global: Individual Record

Company: Teva
Current Parent Company: Teva Pharmaceutical Industries
Parent at the Time of the Penalty Announcement: Teva Pharmaceutical Industries
Jurisdiction: European Commission
Region: Europe
Penalty Currency: Euro
Penalty Amount in Original Currency: 462,600,000
U.S. Dollar Equivalent at the Time of the Penalty Announcement: $499,968,828
Year: 2024
Date: October 30, 2024
Agency: European Commission Directorate-General for Competition
Offense Group: competition-related offenses
Offense Category: anti-competitive practices
Description: The European Commission fined Teva EUR 462.6 million for abusing its dominant position to delay competition to Copaxone, itsmedicine for the treatment of multiple sclerosis. The Commission found that Teva artificially extended the patent protection of Copaxone and systematically spread misleading information about a competing product to hinder its market entry and uptake.
HQ Country of Current Parent: Israel
Ownership Structure of Current Parent: publicly traded
Major Industry of Current Parent: pharmaceuticals
Specific Industry of Current Parent: pharmaceuticals
Source of Data: (click here)
VTG Record ID: VTG24-73603